Ocugen has a broad pipeline which includes both clinical stage and pre-clinical programs addressing large areas of unmet medical need. Our programs are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long term.
Latest Press Releases
FDA Decision Marks First Orphan Drug Designation for Treatment of oGVHD in the U.S.
Company Strengthens Board with Three Key Director Appointments